PortalPublikationenDiagnostic Accuracy of Liquid Biomarkers for Clinically Sign...

Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds

Standard

Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds. / Kawada, Tatsushi; Shim, Sung Ryul; Quhal, Fahad; Rajwa, Pawel; Pradere, Benjamin; Yanagisawa, Takafumi; Bekku, Kensuke; Laukhtina, Ekaterina; von Deimling, Markus; Teoh, Jeremy Yuen-Chun; Karakiewicz, Pierre I; Araki, Motoo; Shariat, Shahrokh F.

in: EUR UROL ONCOL, Jahrgang 7, Nr. 4, 08.2024, S. 649-662.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Kawada, T, Shim, SR, Quhal, F, Rajwa, P, Pradere, B, Yanagisawa, T, Bekku, K, Laukhtina, E, von Deimling, M, Teoh, JY-C, Karakiewicz, PI, Araki, M & Shariat, SF 2024, 'Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds', EUR UROL ONCOL, Jg. 7, Nr. 4, S. 649-662. https://doi.org/10.1016/j.euo.2023.10.029

APA

Kawada, T., Shim, S. R., Quhal, F., Rajwa, P., Pradere, B., Yanagisawa, T., Bekku, K., Laukhtina, E., von Deimling, M., Teoh, J. Y-C., Karakiewicz, P. I., Araki, M., & Shariat, S. F. (2024). Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds. EUR UROL ONCOL, 7(4), 649-662. https://doi.org/10.1016/j.euo.2023.10.029

Vancouver

Kawada T, Shim SR, Quhal F, Rajwa P, Pradere B, Yanagisawa T et al. Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds. EUR UROL ONCOL. 2024 Aug;7(4):649-662. https://doi.org/10.1016/j.euo.2023.10.029

Bibtex

@article{20b23cdd61a3468b8e60205d59bd8ef6,
title = "Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds",
abstract = "ContextMany liquid biomarkers have entered clinical practice with the praise to improve the detection of clinically significant prostate cancer (csPCa), helping avoid unnecessary prostate biopsies.ObjectiveWe aimed to assess the diagnostic accuracy of multianalyte biomarkers for csPCa detection using multiple thresholds.Evidence acquisitionA comprehensive literature search was done through PubMed, Web of Science, and Scopus in March 2023 for prospective and retrospective studies reporting the diagnostic performance of liquid biomarkers for detecting csPCa. The outcomes of interest were the diagnostic performance of liquid biomarkers for csPCa detection and identification of optimal thresholds for each biomarker.Evidence synthesisOverall, 49 studies were eligible for this meta-analysis. Using each representative threshold based on the Youden Index, the pooled sensitivity and specificity for detecting csPCa were 0.85 and 0.37 for prostate cancer gene 3 (PCA3), 0.85 and 0.52 for prostate health index (PHI), 0.87 and 0.58 for four kallikrein (4K), 0.82 and 0.56 for SelectMDx, 0.85 and 0.54 for ExoDx, and 0.82 and 0.59 for mi prostate score (MPS), respectively. The diagnostic odds ratio was highest for 4K (8.84), followed by MPS (7.0) and PHI (6.28). According to the meta-analysis incorporating multiple thresholds, the corresponding sensitivity was 0.77 for 4K, 0.69 for PHI, and 0.63 for PCA3; specificity was 0.72 for PHI, 0.70 for 4K, and 0.69 for PCA3.ConclusionsRegarding the detection of csPCa, 4K had the highest diagnostic performance among the commercial liquid biomarkers. Based on the optimal thresholds calculated by the present meta-analysis, 4K had the highest sensitivity and PHI had the highest specificity for detecting csPCa. Nevertheless, clinical decision-making requires combination strategies between liquid and imaging biomarkers.Patient summaryNovel biomarkers for prostate cancer detection were useful for more accurate diagnosis of clinically significant prostate cancer to avoid unnecessary biopsies.",
author = "Tatsushi Kawada and Shim, {Sung Ryul} and Fahad Quhal and Pawel Rajwa and Benjamin Pradere and Takafumi Yanagisawa and Kensuke Bekku and Ekaterina Laukhtina and {von Deimling}, Markus and Teoh, {Jeremy Yuen-Chun} and Karakiewicz, {Pierre I} and Motoo Araki and Shariat, {Shahrokh F}",
year = "2024",
month = aug,
doi = "10.1016/j.euo.2023.10.029",
language = "English",
volume = "7",
pages = "649--662",
journal = "EUR UROL ONCOL",
issn = "2588-9311",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds

AU - Kawada, Tatsushi

AU - Shim, Sung Ryul

AU - Quhal, Fahad

AU - Rajwa, Pawel

AU - Pradere, Benjamin

AU - Yanagisawa, Takafumi

AU - Bekku, Kensuke

AU - Laukhtina, Ekaterina

AU - von Deimling, Markus

AU - Teoh, Jeremy Yuen-Chun

AU - Karakiewicz, Pierre I

AU - Araki, Motoo

AU - Shariat, Shahrokh F

PY - 2024/8

Y1 - 2024/8

N2 - ContextMany liquid biomarkers have entered clinical practice with the praise to improve the detection of clinically significant prostate cancer (csPCa), helping avoid unnecessary prostate biopsies.ObjectiveWe aimed to assess the diagnostic accuracy of multianalyte biomarkers for csPCa detection using multiple thresholds.Evidence acquisitionA comprehensive literature search was done through PubMed, Web of Science, and Scopus in March 2023 for prospective and retrospective studies reporting the diagnostic performance of liquid biomarkers for detecting csPCa. The outcomes of interest were the diagnostic performance of liquid biomarkers for csPCa detection and identification of optimal thresholds for each biomarker.Evidence synthesisOverall, 49 studies were eligible for this meta-analysis. Using each representative threshold based on the Youden Index, the pooled sensitivity and specificity for detecting csPCa were 0.85 and 0.37 for prostate cancer gene 3 (PCA3), 0.85 and 0.52 for prostate health index (PHI), 0.87 and 0.58 for four kallikrein (4K), 0.82 and 0.56 for SelectMDx, 0.85 and 0.54 for ExoDx, and 0.82 and 0.59 for mi prostate score (MPS), respectively. The diagnostic odds ratio was highest for 4K (8.84), followed by MPS (7.0) and PHI (6.28). According to the meta-analysis incorporating multiple thresholds, the corresponding sensitivity was 0.77 for 4K, 0.69 for PHI, and 0.63 for PCA3; specificity was 0.72 for PHI, 0.70 for 4K, and 0.69 for PCA3.ConclusionsRegarding the detection of csPCa, 4K had the highest diagnostic performance among the commercial liquid biomarkers. Based on the optimal thresholds calculated by the present meta-analysis, 4K had the highest sensitivity and PHI had the highest specificity for detecting csPCa. Nevertheless, clinical decision-making requires combination strategies between liquid and imaging biomarkers.Patient summaryNovel biomarkers for prostate cancer detection were useful for more accurate diagnosis of clinically significant prostate cancer to avoid unnecessary biopsies.

AB - ContextMany liquid biomarkers have entered clinical practice with the praise to improve the detection of clinically significant prostate cancer (csPCa), helping avoid unnecessary prostate biopsies.ObjectiveWe aimed to assess the diagnostic accuracy of multianalyte biomarkers for csPCa detection using multiple thresholds.Evidence acquisitionA comprehensive literature search was done through PubMed, Web of Science, and Scopus in March 2023 for prospective and retrospective studies reporting the diagnostic performance of liquid biomarkers for detecting csPCa. The outcomes of interest were the diagnostic performance of liquid biomarkers for csPCa detection and identification of optimal thresholds for each biomarker.Evidence synthesisOverall, 49 studies were eligible for this meta-analysis. Using each representative threshold based on the Youden Index, the pooled sensitivity and specificity for detecting csPCa were 0.85 and 0.37 for prostate cancer gene 3 (PCA3), 0.85 and 0.52 for prostate health index (PHI), 0.87 and 0.58 for four kallikrein (4K), 0.82 and 0.56 for SelectMDx, 0.85 and 0.54 for ExoDx, and 0.82 and 0.59 for mi prostate score (MPS), respectively. The diagnostic odds ratio was highest for 4K (8.84), followed by MPS (7.0) and PHI (6.28). According to the meta-analysis incorporating multiple thresholds, the corresponding sensitivity was 0.77 for 4K, 0.69 for PHI, and 0.63 for PCA3; specificity was 0.72 for PHI, 0.70 for 4K, and 0.69 for PCA3.ConclusionsRegarding the detection of csPCa, 4K had the highest diagnostic performance among the commercial liquid biomarkers. Based on the optimal thresholds calculated by the present meta-analysis, 4K had the highest sensitivity and PHI had the highest specificity for detecting csPCa. Nevertheless, clinical decision-making requires combination strategies between liquid and imaging biomarkers.Patient summaryNovel biomarkers for prostate cancer detection were useful for more accurate diagnosis of clinically significant prostate cancer to avoid unnecessary biopsies.

U2 - 10.1016/j.euo.2023.10.029

DO - 10.1016/j.euo.2023.10.029

M3 - SCORING: Review article

C2 - 37981495

VL - 7

SP - 649

EP - 662

JO - EUR UROL ONCOL

JF - EUR UROL ONCOL

SN - 2588-9311

IS - 4

ER -